This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 278453.
ClinicalTrials.gov Identifier:
NCT02035540
News
Decellularized pulmonary homografts exhibit better results than bovine jugular vein conduits
A recent publication in the journal of Cell and Tissue Banking analyzed the results of a matched comparison of decellularized pulmonary homografts (DPH) and bovine jugular vein (BJV) conduits for pulmonary valve replacement in...
New study analyzes early antibody binding to decellularized homografts
Semi-quantitative analysis by a newly developed Dot-Blot showed early binding of preformed antibody binding in 20 consecutive patients, which were followed after pulmonary and aortic valve replacement with cell-free homografts....
European Journal for Cardiothoracic Surgery publishes ESPOIR 5-year data
A 5-year analysis of ESPOIR Trial patients was performed to provide an insight into the midterm performance of decellularized pulmonary homografts (DPH). ESPOIR Trial and Registry patients were matched with cryopreserved...
Welcome to ESPOIR
Beginning in January 2012, the European Union will fund the European Clinical Study for the Application of Regenerative Heart Valves (ESPOIR) trial, coordinated by the Hannover Medical School, Germany, with a grant of 5.2 Million Euros for a period of four years. The aim of ESPOIR is to transplant a heart valve, which is tolerated by the patient’s immune system, lasts a lifetime and, for children, even holds the potential to grow with the patient.